<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25223501</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>02</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">2326-5205</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>66</Volume>
<Issue>11</Issue>
<PubDate>
<Year>2014</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Arthritis &amp; rheumatology (Hoboken, N.J.)</Title>
</Journal>
<ArticleTitle>Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS).</ArticleTitle>
<Pagination>
<MedlinePgn>3227-32</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Objective: To describe the pregnancy course and outcome, and use of anakinra, a recombinant selective IL-1 receptor blocker, during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal onset multi-system inflammatory disease (NOMID). Methods: Women currently enrolled in natural history protocols (NCT00059748, and/or NCT00069329 under IND) who have been pregnant were included. Subjects underwent a structured, standardized interview with regards to maternal health, pregnancy and fetal outcomes. Medical records were reviewed. Results: Nine women (four with FCAS, one with MWS and four with NOMID) reported one to four pregnancies, each resulting in a total of fifteen FCAS, three MWS, and six NOMID pregnancies. Six births from FCAS mothers and three births from NOMID mothers occurred while patients were receiving anakinra. If a woman became pregnant while taking anakinra, the pre-pregnancy anakinra dose was continued. Anakinra dose was increased during one twin pregnancy. No preterm births or serious complications of pregnancy were observed. One fetus of the twin pregnancy had renal agenesis and suffered fetal demise. Genetic testing showed the deceased twin carried the same NLRP3 c.785T&gt;C, p.V262A mutation as the mother. The other twin is healthy and mutation negative. Conclusions: Anakinra was continued during pregnancy in women with CAPS and provided significant, persistent CAPS symptom relief while continuing to prevent the long-term sequelae of CAPS. Anakinra was well tolerated. Although a causal relation between anakinra and renal agenesis seems unlikely, further safety data are needed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Zenas</ForeName>
<Initials>Z</Initials>
<AffiliationInfo>
<Affiliation>Eunice Kennedy Shriver National Institute of Child  Health and Human Development, NIH, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spong</LastName>
<ForeName>Catherine Y</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jesus</LastName>
<ForeName>Adriana A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Davis</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Plass</LastName>
<ForeName>Nicole</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stone</LastName>
<ForeName>Deborah L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chapelle</LastName>
<ForeName>Dawn</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hoffmann</LastName>
<ForeName>Patrycja</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kastner</LastName>
<ForeName>Daniel L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barron</LastName>
<ForeName>Karyl</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goldbach-Mansky</LastName>
<ForeName>Raphaela T</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stratton</LastName>
<ForeName>Pamela</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00059748</AccessionNumber>
<AccessionNumber>NCT00069329</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>ZIA AR041138-11</GrantID>
<Acronym>NULL</Acronym>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arthritis Rheumatol</MedlineTA>
<NlmUniqueID>101623795</NlmUniqueID>
<ISSNLinking>2326-5191</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C536482">Hereditary renal agenesis</SupplMeshName>
</SupplMeshList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002985">Clinical Protocols</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000013">Congenital Abnormalities</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056587">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005315">Fetal Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053590">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007407">Interviews as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000151">congenital</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011256">Pregnancy Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>02</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>06</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>07</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2014</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2014</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>2</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25223501</ArticleId>
<ArticleId IdType="doi">10.1002/art.38811</ArticleId>
<ArticleId IdType="pmc">PMC4323990</ArticleId>
<ArticleId IdType="mid">NIHMS629290</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Pediatr. 1982 Nov;101(5):738-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7131150</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Hum Genet. 2002 Jul;71(1):198-203</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12032915</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Q J Med. 1962 Apr;31:235-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14476827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2006 Aug 10;355(6):581-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16899778</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Rheum Dis. 2009 Nov;68(11):1794-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19822718</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BJOG. 2001 Nov;108(11):1164-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11762656</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatrics. 2013 Sep;132(3):e796-809</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23979084</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arthritis Rheum. 2002 Dec;46(12):3340-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12483741</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2004 Apr 1;103(7):2809-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14630794</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Reprod. 2004 Apr;19(4):1025-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14990546</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Fertil Steril. 2004 Oct;82(4):799-804</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15482749</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Obstet Gynecol. 2010 May;115(5):930-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20410765</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Rheum Dis. 2011 Mar;70(3):495-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21109514</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arthritis Rheum. 2011 Nov;63(11):3625-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21702021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arthritis Rheum. 2012 Jul;64(7):2375-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22294344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Birth Defects Res A Clin Mol Teratol. 2013 Aug;97(8):554-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23913417</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Scand J Rheumatol Suppl. 1987;66:57-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3482735</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>